Many patients diagnosed with prostate cancer encounter a type of imaging study they may never have heard of before during treatment planning:
Ga-68 PSMA PET/CT (Gallium-68 PSMA PET/CT)
Some of the most common questions patients ask include:
In recent years, Ga-68 PSMA PET/CT has become one of the most important advances in the evaluation of prostate cancer.
This technology allows physicians to assess the extent of prostate cancer with much greater accuracy and helps create more personalized treatment plans.
PSMA stands for Prostate-Specific Membrane Antigen, a protein that is found in higher concentrations on the surface of many prostate cancer cells.
PSMA-targeted imaging agents are designed to attach to these cells, making them easier to detect during imaging studies.
As a result, prostate cancer cells can be visualized with a high degree of sensitivity.
Gallium-68 (Ga-68) is a radioactive tracer used for medical imaging.
When a PSMA-targeting molecule is labeled with Ga-68 and injected into a vein, it can bind to prostate cancer cells throughout the body.
PET/CT imaging can then identify areas where the tracer has accumulated, helping physicians locate prostate cancer cells.
For this reason, the examination is commonly referred to as:
During the procedure, a small amount of a Ga-68 PSMA tracer is injected intravenously.
After an appropriate waiting period, PET/CT imaging is performed.
This allows detailed evaluation of:
The goal is to determine the location and extent of prostate cancer as accurately as possible.
Not every prostate cancer patient requires this examination.
It is most commonly recommended in situations such as:
The primary objective is to assess whether the disease has spread beyond the prostate.
One of the most important questions in prostate cancer management is:
Is the cancer confined to the prostate, or has it spread outside the gland?
Ga-68 PSMA PET/CT can provide valuable information to answer this question.
In particular, it may help detect:
These findings can directly influence treatment decisions.
No.
Although Ga-68 PSMA PET/CT is one of the most sensitive imaging tools currently available for prostate cancer, no imaging test is perfect.
Very small cancer deposits may occasionally remain undetected.
In addition, not every area of tracer uptake necessarily represents cancer.
For this reason, results should always be interpreted in conjunction with:
This is a common question among patients.
A negative or “clean” Ga-68 PSMA PET/CT scan generally indicates that no obvious spread of prostate cancer outside the prostate has been detected.
This is usually considered a favorable finding.
However, microscopic cancer cells may still be below the detection limits of current imaging technology.
Therefore, imaging results should always be interpreted within the broader clinical context.
Following robotic radical prostatectomy or radiation therapy, some patients may experience a rise in PSA levels.
This situation is known as biochemical recurrence.
In such cases, Ga-68 PSMA PET/CT is frequently used to:
Yes.
In some patients, PSMA PET/CT findings can significantly alter treatment decisions.
For example:
For this reason, PSMA PET/CT has become an important component of modern prostate cancer management.
In general, yes.
Ga-68 PSMA PET/CT is widely used around the world and is considered a safe imaging technique.
Specific preparation and post-procedure instructions may vary between imaging centers, so patients should always follow the recommendations provided by their healthcare team.
In recent years, Ga-68 PSMA PET/CT has become a key tool for both staging and restaging prostate cancer.
This technology allows:
As a result, it has transformed the way prostate cancer is evaluated and managed.
Ga-68 PSMA PET/CT is one of the most advanced imaging techniques currently available for the staging and follow-up of prostate cancer.
Particularly in patients with intermediate- and high-risk disease, it can provide valuable information regarding whether the cancer has spread beyond the prostate.
If your physician has recommended a Ga-68 PSMA PET/CT scan, this examination may help ensure a more accurate assessment of your disease and contribute to the development of the most appropriate treatment plan for your individual situation.
Assoc. Prof. Dr. Serdar Yalçın
Urology Specialist
Prostate Cancer • Ga-68 PSMA PET/CT • Robotic Urology • Urologic Oncology • Personalized Cancer Care
Bu makalenin DoktorTakvimi web sitesinde yayımlanması, yazarın açık izniyle yapılmaktadır. Web sitesindeki tüm içerikler, fikri ve sınai mülkiyet mevzuatı kapsamında uygun şekilde korunmaktadır.
DocPlanner Teknoloji A.Ş. web sitesi tıbbi tavsiye sunmaz. Bu sayfanın içeriği, metinler, grafikler, görseller ve diğer materyaller de dahil olmak üzere, yalnızca bilgilendirme amacıyla oluşturulmuştur ve tıbbi tavsiye, teşhis veya tedavinin yerini almak amacı taşımaz. Herhangi bir sağlık sorununuzla ilgili şüpheniz varsa, bir uzmana danışınız.
11/06/2026
11/06/2026
11/06/2026